Advertisement

Loading...

ChitogenX Inc.

CHGX.CNCNQ
Healthcare
Biotechnology
$0.005
$0.00(0.00%)
Canadian Market opens in 17h 29m

ChitogenX Inc. Fundamental Analysis

ChitogenX Inc. (CHGX.CN) shows moderate financial fundamentals with a PE ratio of -0.23, profit margin of 0.00%, and ROE of 19.40%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

PEG Ratio-0.02

Areas of Concern

Operating Margin0.00%
Current Ratio0.07
We analyze CHGX.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 46.0/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
46.0/100

We analyze CHGX.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

CHGX.CN struggles to generate sufficient returns from assets.

ROA > 10%
-2.91%

Valuation Score

Excellent

CHGX.CN trades at attractive valuation levels.

PE < 25
-0.23
PEG Ratio < 2
-0.02

Growth Score

Moderate

CHGX.CN shows steady but slowing expansion.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
83.62%

Financial Health Score

Moderate

CHGX.CN shows balanced financial health with some risks.

Debt/Equity < 1
-0.63
Current Ratio > 1
0.07

Profitability Score

Weak

CHGX.CN struggles to sustain strong margins.

ROE > 15%
19.40%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is CHGX.CN Expensive or Cheap?

P/E Ratio

CHGX.CN trades at -0.23 times earnings. This suggests potential undervaluation.

-0.23

PEG Ratio

When adjusting for growth, CHGX.CN's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values ChitogenX Inc. at -0.06 times its book value. This may indicate undervaluation.

-0.06

EV/EBITDA

Enterprise value stands at 5.11 times EBITDA. This is generally considered low.

5.11

How Well Does CHGX.CN Make Money?

Net Profit Margin

For every $100 in sales, ChitogenX Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $19.40 in profit for every $100 of shareholder equity.

19.40%

ROA

ChitogenX Inc. generates $-2.91 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.91%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

CHGX.CN converts -2.43% of its market value into free cash.

-2.43%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.23

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.06

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.63

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.07

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.19

vs 25 benchmark

ROA

Return on assets percentage

-2.91

vs 25 benchmark

ROCE

Return on capital employed

1.000

vs 25 benchmark

How CHGX.CN Stacks Against Its Sector Peers

MetricCHGX.CN ValueSector AveragePerformance
P/E Ratio-0.2327.91 Better (Cheaper)
ROE19.40%687.00% Weak
Net Margin0.00%-45285.00% (disorted) Weak
Debt/Equity-0.630.33 Strong (Low Leverage)
Current Ratio0.072795.76 Weak Liquidity
ROA-291.01%-13557.00% (disorted) Weak

CHGX.CN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews ChitogenX Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

78.03%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

75.29%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ